Cellular Biomedicine Group (NASDAQ:CBMG) Upgraded at BidaskClub

BidaskClub upgraded shares of Cellular Biomedicine Group (NASDAQ:CBMG) from a sell rating to a hold rating in a research note released on Friday, BidAskClub reports.

Other equities analysts also recently issued research reports about the stock. ValuEngine raised shares of Cellular Biomedicine Group from a hold rating to a buy rating in a research note on Thursday, August 1st. Cantor Fitzgerald initiated coverage on shares of Cellular Biomedicine Group in a research note on Tuesday, June 25th. They set an overweight rating and a $27.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $27.50.

NASDAQ:CBMG opened at $14.84 on Friday. The company has a market cap of $281.05 million, a P/E ratio of -7.27 and a beta of 2.77. Cellular Biomedicine Group has a fifty-two week low of $10.98 and a fifty-two week high of $25.00. The firm’s 50 day moving average is $12.78 and its two-hundred day moving average is $15.44.

Cellular Biomedicine Group (NASDAQ:CBMG) last posted its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.63) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.10). Cellular Biomedicine Group had a negative return on equity of 44.32% and a negative net margin of 17,921.62%. As a group, research analysts anticipate that Cellular Biomedicine Group will post -2.39 earnings per share for the current year.

A number of large investors have recently bought and sold shares of CBMG. BNP Paribas Arbitrage SA raised its stake in shares of Cellular Biomedicine Group by 1,641.8% in the 1st quarter. BNP Paribas Arbitrage SA now owns 2,456 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 2,315 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Cellular Biomedicine Group by 13.2% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 28,526 shares of the biotechnology company’s stock valued at $472,000 after acquiring an additional 3,323 shares during the period. Bank of America Corp DE raised its stake in shares of Cellular Biomedicine Group by 207.8% in the 4th quarter. Bank of America Corp DE now owns 10,448 shares of the biotechnology company’s stock valued at $185,000 after acquiring an additional 7,054 shares during the period. Northern Trust Corp raised its stake in shares of Cellular Biomedicine Group by 5.0% in the 2nd quarter. Northern Trust Corp now owns 170,273 shares of the biotechnology company’s stock valued at $2,815,000 after acquiring an additional 8,101 shares during the period. Finally, Platinum Investment Management Ltd. raised its stake in shares of Cellular Biomedicine Group by 2.9% in the 2nd quarter. Platinum Investment Management Ltd. now owns 672,885 shares of the biotechnology company’s stock valued at $11,123,000 after acquiring an additional 19,170 shares during the period. 20.37% of the stock is currently owned by institutional investors.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases.

Featured Article: What is the accumulation/distribution indicator?

Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.